

S/N 09/754,826

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Mohamed E. El Halawani et al.

Examiner: Unknown


Serial No.: 09/754,826

Group Art Unit: Unknown

Filed: January 4, 2001

Docket: 600.492US1

Title: USE OF PASSIVE MYOSTATIN IN ABRUPTIZATION



PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the "Notice to File Missing Parts of Nonprovisional Application" mailed May 11, 2001, please amend the above-identified patent application as follows:

In the Specification

Please enter the enclosed SEQUENCE LISTING into the specification.

Please substitute the paragraph in the appendix entitled "Clean Version of the First Full Paragraph of Page 46" for the first full paragraph of page 46 of the specification. Specific amendments to this paragraph are detailed in the following marked-up paragraph:

Myostatin peptides were prepared. The peptides were C1 (Asn-Met-Leu-Tyr-Phe-Asn-Gly-Lys-Glu-Gln-Ile-Ile-Tyr-Gly-Lys-Ile; residues 83-98 [residues 5-15]; SEQ ID NO:4), D1 (Asp-Cys-Asp-Glu-His-Ser-Thr-Glu-Ser-Arg-Cys; residues 5-15 [residues 33-41]; SEQ ID NO:5), and E1 (Ile-Ala-Pro-Lys-Arg-Tyr-Lys-Ala-Asn; residues 33-41 [residues 83-98]; SEQ ID NO:6). Each received a peptide immunogen and the sequences were chosen based on relative hydrophilicity/hydrophobicity.

Remarks

This Preliminary Amendment and the above-referenced SEQUENCE LISTING are filed in part to conform the above-referenced application to the requirements of 37 C.F.R. §§ 1.821 - 1.825. In accordance with 37 C.F.R. § 1.821(e), a copy of the above-submitted SEQUENCE LISTING in ASCII computer readable form is also submitted herewith. The contents of the paper version of the SEQUENCE LISTING and the computer readable form being submitted herewith are the same, and the paper copy of the SEQUENCE LISTING and the computer readable form of the SEQUENCE LISTING do not include new matter.

09754826-101601

The amendments to page 46 of the specification are made to identify the residues of myostatin represented by SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6. These amendments are supported by page 46 of the specification and by Figure 1.

Conclusion

Applicant respectfully submits that the claims are in condition for allowance and notification to that effect is requested. The Examiner is invited to telephone Applicant's attorney (612-373-6959) to facilitate prosecution of this application.

If necessary, please charge any additional fees or credit overpayment to Deposit Account No. 19-0743.


Respectfully submitted,

MOHAMED E. EL HALAWANI ET AL.

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 373-6959

Date October 11, 2001

By 
Janet E. Embretson
Reg. No. 39,665

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner of Patents, Washington, D.C. 20231, on this 11 day of October, 2001.

Seattamattie Greg
Name

Seattamattie Greg
Signature

Clean Version of the First Full Paragraph of Page 46

USE OF PASSIVE MYOSTATIN IMMUNIZATION

Applicant: Mohamed E. El Halawani et al.

Serial No.: 09/754,826

Myostatin peptides were prepared. The peptides were C1 (Asn-Met-Leu-Tyr-Phe-Asn-Gly-Lys-Glu-Gln-Ile-Ile-Tyr-Gly-Lys-Ile; residues 83-98; SEQ ID NO:4), D1 (Asp-Cys-Asp-Glu-His-Ser-Thr-Glu-Ser-Arg-Cys; residues 5-15; SEQ ID NO:5), and E1 (Ile-Ala-Pro-Lys-Arg-Tyr-Lys-Ala-Asn; residues 33-41; SEQ ID NO:6). Each received a peptide immunogen and the sequences were chosen based on relative hydrophilicity/hydrophobicity.

Page 46 of 60